A new analysis being presented at the European Congress on Obesity (ECO25) in Malaga, Spain (11–14 May), finds that around ...

In patients with overweight/obesity and/or diabetes, glucagon-like peptide 1 receptor agonist (GLP1-RA) treatment is not associated ...

Improvements with GLP-1 RAs in psoriasis and other chronic skin diseases point to their increased use in dermatology and a ...

Learn how emerging technologies are enhancing patient engagement and treatment strategies in everyday practice.

The benefit was seen as soon as 3 months. Investigators say there should be no delaying treatment for eligible patients.

Children who are living with severe obesity are more likely to experience a clinically relevant change in BMI when GLP-1 ...

Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

Despite the approval of second-generation antiobesity medications, metabolic and bariatric surgery (MBS) use among U.S.

GLP1 drugs are changing patients eating and grocery shopping habits - 2 News Oklahoma's Cathy Tatom hears how from a patient, ...

CEO Andrew Dudum said the funds will allow the company to grow internationally and invest in artificial intelligence.

Data from a Swedish clinic suggests that GLP-1 drugs can be effective in managing severe obesity in children, offering a ...

Scientists at EPFL and AstraZeneca have developed a method to map the atomic-level structure of amorphous drugs, demonstrated ...